[Federal Register Volume 78, Number 223 (Tuesday, November 19, 2013)]
[Page 69429]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-27601]



National Institutes of Health

Prospective Grant of Exclusive License: The Development of 
Modified T-cells for the Treatment of Multiple Myeloma

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.


SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
Part 404, that the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant to Thirsty Brook 
Bioscience, Inc., of an exclusive evaluation option license to practice 
the inventions embodied in the following US Patent Applications (and 
all continuing applications and foreign counterparts): Serial No. 61/
622,6008 entitled, ``Chimeric Antigen Receptors Targeting B-cell 
Maturation Antigen'' [HHS Ref. E-040-2012/0-US-01]. The patent rights 
in these inventions have been assigned to the Government of the United 
States of America.
    The prospective exclusive evaluation option license territory may 
be worldwide, and the field of use may be limited to:

    ``The research, development, and manufacture of chimeric antigen 
receptor (CAR)-expressing human T-cells directed against B-cell 
Maturation Antigen (BCMA) for the treatment of multiple myeloma.''

    Upon the expiration or termination of the exclusive evaluation 
option license, Thirsty Brook Bioscience, Inc. will have the exclusive 
right to execute an exclusive commercialization license which will 
supersede and replace the exclusive evaluation option license with no 
greater field of use and territory than granted in the exclusive 
evaluation option license.

DATES: Only written comments or applications for a license (or both) 
which are received by the NIH Office of Technology Transfer on or 
before December 4, 2013 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
evaluation option license should be directed to: Patrick McCue, Ph.D., 
Licensing and Patenting Manager, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; Telephone: (301) 435-5560; Facsimile: (301) 
402-0220; Email: [email protected].

SUPPLEMENTARY INFORMATION: The invention concerns a series of CARs that 
specifically target BCMA (a.k.a. CD269), a protein that is highly 
expressed on the surface of multiple myeloma cells. The patent rights 
include claims to vectors incorporating the CARs, as well as methods of 
destroying multiple myeloma cells using T-cells engineered to express a 
    The prospective exclusive evaluation option license is being 
considered under the small business initiative launched on 1 October 
2011, and will comply with the terms and conditions of 35 U.S.C. 209 
and 37 CFR part 404. The prospective exclusive evaluation option 
license, and a subsequent exclusive commercialization license, may be 
granted unless the NIH receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404 within fifteen 
(15) days from the date of this published notice.
    Complete applications for a license in the field of use filed in 
response to this notice will be treated as objections to the grant of 
the contemplated exclusive evaluation option license. Comments and 
objections submitted to this notice will not be made available for 
public inspection and, to the extent permitted by law, will not be 
released under the Freedom of Information Act, 5 U.S.C. 552.

    Dated: November 13, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development & Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-27601 Filed 11-18-13; 8:45 am]